Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A round of late-afternoon buying boosted the Dow Jones average to another record high on Friday as rising optimism around the global economic...
Wedbush analyst Liana Moussatos has downgraded shares of Grayburg Vision (GRAY) from outperform to neutral.She also cut her price target to $8 from $41.Moussatos writes that she is "perplexed" at secondary endpoint results from top-line data on the company's lead candidate, GB-102, for wet ag...
Gainers: Exela Technologies (XELA) +163%.Oragenics (OGEN) +47%.ReneSola (SOL) +42%.Auris Medical (EARS) +39%.The9 (NCTY) +37%.Canaan (CAN) +36%.AnPac Bio-Medical Science (ANPC) +36%.Riot Blockchain (RIOT) +35%.Washington Prime (WPG) +30%.Socket Mobile (SCKT) +23%.Losers: G...
Piper Sandler analyst Christopher Raymond has downgraded shares of Grayburg Vision (GRAY) to neutral from overweight.He has also cut his price target from $27 to $10.Raymond said the release earlier today of top-line data from Grayburg's phase 2b ALTISSIMO study of GB-102, the company's...
Graybug Vision (GRAY) posts preliminary topline data from the 12-month treatment phase of its Phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (wet AMD), the company's proprietary microparticle depot formulation of sunitinib malate injected int...
Median time to first supportive therapy was 5 months for GB-102 1mg 48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 months Control of retinal thickness was consistent across all trial arms Mean best-corrected visual acuity with GB-102 1mg...
Graybug Vision (GRAY): FY GAAP EPS of -$5.25.Cash and cash equivalents of $33.42M.Press Release For further details see: Graybug Vision reports FY results
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today provided an update on recent corporate d...
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced that Fred Guerar...
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment ...
News, Short Squeeze, Breakout and More Instantly...
Graybug Vision Inc. Company Name:
GRAY Stock Symbol:
NASDAQ Market:
- CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” - Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 - Phase 2b results ...
REDWOOD CITY, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its tradin...
Toronto, Ontario--(Newsfile Corp. - March 2, 2023) - Graycliff Exploration Limited (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) (the " Company " or " Graycliff ") is pleased to announce that it has acquired the Lunge Project ("Lunge") located on the prolific Canadian Shield in the Sudbury Basin...